Midlife women are mixing menopause drugs with anti ageing pills and no one is checking the risks

Independent prescribing pharmacist, Richa Puri warns that perimenopausal women are drifting into unregulated self‑prescribed “polypharmacy” as they mix prescriptions with self‑directed “hallmarks of ageing” programmes, with no clear medical oversight.

Last weekend, thousands visited the Longevity Show at London’s Tobacco Dock, billed as “the UK’s first longevity festival” promising a way to discover “what really works for living healthier, longer”. It’s part of a wider boom: specialist longevity clinics, medical summits and global congresses now promote prevention, health optimisation and menopause in practice as key growth areas – even this year’s obsession with peptides.

Alongside clinics, biological‑age testing has become one of the fastest‑moving spaces in consumer health. Many tests now arrive with supplement programmes or access to private longevity services, and marketing is increasingly directed at midlife women.

“Women in their 40s and 50s have become the key demographic for this new longevity business model,” says Richa Puri, an independent prescribing pharmacist. “They’re told they can control how fast they age, but the practical advice they’re given is often a shopping list of tests and pills.”

Science and hype: from hallmarks of ageing to clinic packages

Underpinning much of the new marketing is the “hallmarks of ageing” framework, developed over the past decade to describe twelve cellular and molecular processes that change as we grow older. Recent reviews have extended the framework and used it to organise research into longevity drugs and interventions.

In the consumer market, these “hallmarks” have been translated into sales material. Clinics and brands now promote “hallmark‑targeting” products like supplement stacks, and I.V. treatments, often with promises to lower biological age by a certain number of years, despite continuing debate in scientific journals about reliability.

“The hallmarks were intended as a research framework, not a menu for retail packages,” says a professor of ageing biology at a UK university, who has studied biological clocks. “We simply don’t yet have robust evidence that changing a score on a commercial test with a supplement stack will translate into meaningful reductions in disease or mortality for an individual patient.”

Midlife women are in the crosshairs of hormones, meds and stacks, and the risk is the combination

For midlife women, timing is sensitive. Perimenopause is associated with fluctuating hormones, sleep disruption, changes in blood sugar handling, weight and increased vulnerability to mental health issues. Long‑term risks of cardiovascular disease, osteoporosis and later‑life cognitive decline also begin to diverge in this period, making the 40s and 50s a key window for prevention.

At the same time, medicine‑use is creeping steadily upwards. Johns Hopkins researchers warn that

polypharmacy, commonly defined as five or more regular medicines, is associated with higher rates of drug interactions, falls, kidney problems and hospital admission in older adults.

A UK‑focused analysis in The Pharmaceutical Journal found that almost 40% of older people with polypharmacy received at least one potentially inappropriate prescription when started on type 2 diabetes treatment.

Recent Australian data suggest the number of people living with polypharmacy nearly doubled over a decade, with growth increasingly driven by middle‑aged adults rather than only the over‑75s.

“This is the first generation going through perimenopause with both a high baseline medicine burden and a wave of new longevity products pitched directly at them,” says clinical pharmacist, independent prescriber and registered nutritional therapist Richa Puri, who specialises in women’s hormonal health. “By the time many women find me, they’re on three or four prescriptions and taking a handful of supplements they’ve chosen themselves to ‘target’ hallmarks or biological age.”

Puri says her patients often self-prescribe, which can lead to issues without medical or professional oversight. For example, a midlife patient might be prescribed HRT, thyroid medication or a GLP‑1 for weight and blood sugar; she might also be taking an antidepressant or blood‑pressure tablet, then add supplements such as magnesium, omega‑3, collagen, berberine, probiotics and an NAD‑style longevity product on top. “Individually, none of these is necessarily unreasonable,” she says. “The risk is in the combination, because no medical professional has reviewed what’s being taken against her history, lab results and medical priorities.”

“A kind of DIY longevity clinic in the bathroom cabinet”

Clinicians say that a combination of complex physiology, multiple prescriptions and consumer longevity culture is creating blind spots for health systems that were designed around ageing in the 70s and 80s, not the 40s and 50s.

“What we’re seeing now is a kind of DIY longevity clinic in the kitchen cupboard,” says Richa. “Patients bring in expensive biological‑age reports and bags of supplements, but those products often don’t show up accurately in our records, and appointment slots are too short to review the entire regimen.”

The UK’s renewed Women’s Health Strategy, published this spring, pledges to expand menopause and post‑menopausal services and improve access to pain and bleeding clinics by the end of 2026. But it says little about how NHS services should respond to the rise of private longevity clinics, direct‑to‑consumer testing and over‑the‑counter stacks used alongside prescribed medicines.

Puri argues that this gap is particularly acute for women aged 40 – 55. “We’ve invested in important awareness messages about perimenopause, but we haven’t yet caught up with the reality that these same women are being told they can and should self‑manage their biological age,” she says. “Without a prescriber who understands both hallmarks of science and drug–supplement interactions, it becomes guesswork.”

Hallmarks into action: what experts say women can do

Behind the marketing, experts broadly agree on the handful of interventions that are most likely to improve the ageing path for midlife women, whether they ever take a biological‑age test. Richa frames this in practical terms for her patients:

Sleep: “For many women, getting hot flushes and night sweats under control with HRT or non‑hormonal medication is the first real longevity intervention, because it stabilises sleep and allows the brain and immune system to repair properly.”
Movement and muscle: “We talk less about weight and more about strength, balance and metabolic flexibility. Resistance training seems to pay dividends across the longevity hallmarks that matter for blood sugar, bone and brain.”
Nutrition and alcohol: “Helping women move towards a Mediterranean‑leaning diet and examine their drinking is more impactful than any single supplement for most people.”
Stress and load: “The 45- 55 window is often peak stress; work, teens, parents, health, and chronic stress shows up in telomeres and inflammatory markers. Sometimes we need medication or therapy here as much as lifestyle advice.”

Only then, Richa says, does she start discussing targeted medications or supplement combinations that might make sense for a given woman, such as HRT for severe vasomotor symptoms and bone protection, or carefully selected products for gut health or metabolic support.

Calls for earlier reviews and clearer regulation

Experts say the policy response is lagging behind consumer behaviour. Puri believes part of the answer lies in bringing prescribing expertise into the longevity conversation earlier. “We should be offering full medication and supplement interaction reviews to midlife women in the same way we offer medication reviews to older adults,” she says. “That means sitting down with a prescriber or a qualified nutritionist who would be best placed to offer advice.”

Leave a Reply

Your email address will not be published. Required fields are marked *